UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 31, 2022 |
SQZ BIOTECHNOLOGIES COMPANY
(Exact name of Registrant as Specified in Its Charter)
Delaware | 001-39662 | 46-2431115 | ||
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||
|
|
|
|
|
200 Arsenal Yards Blvd Suite 210 |
| |||
Watertown, Massachusetts |
| 02472 | ||
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: 617 758-8672 |
N/A |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
| Trading |
|
|
Common Stock, $0.001 par value per share |
| SQZ |
| The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On May 31, 2022, SQZ Biotechnologies Company (the "Company") issued a press release announcing the appointment of Marshelle Smith Warren, M.D. as the Company's chief medical officer, effective June 1, 2022.
A copy of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
|
|
|
Exhibit |
| Description |
99.1 |
| Press release issued by SQZ Biotechnologies Company on May 31, 2022. |
104 |
| Cover Page Interactive Data File (embedded with the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
| SQZ BIOTECHNOLOGIES COMPANY |
|
|
|
|
Date: | May 31, 2022 | By: | /s/ Lawrence Knopf |
|
|
| Lawrence Knopf |